T0	KEYPHRASE-NOTYPES 0 5	Signs
T1	KEYPHRASE-NOTYPES 10 18	symptoms
T2	KEYPHRASE-NOTYPES 50 72	musculoskeletal system
T3	KEYPHRASE-NOTYPES 92 111	investigators
T4	KEYPHRASE-NOTYPES 134 155	retrospective studies
T5	KEYPHRASE-NOTYPES 159 167	patients
T6	KEYPHRASE-NOTYPES 180 198	early Lyme disease
T7	KEYPHRASE-NOTYPES 220 234	high incidence
T8	KEYPHRASE-NOTYPES 238 253	continued signs
T9	KEYPHRASE-NOTYPES 258 266	symptoms
T10	KEYPHRASE-NOTYPES 282 291	treatment
T11	KEYPHRASE-NOTYPES 311 318	Shadick
T12	KEYPHRASE-NOTYPES 341 348	percent
T13	KEYPHRASE-NOTYPES 352 360	patients
T14	KEYPHRASE-NOTYPES 366 379	suburban area
T15	KEYPHRASE-NOTYPES 390 405	endemic disease
T16	KEYPHRASE-NOTYPES 420 426	Boston
T17	KEYPHRASE-NOTYPES 452 470	early Lyme disease
T18	KEYPHRASE-NOTYPES 475 493	long-term sequelae
T19	KEYPHRASE-NOTYPES 505 514	arthritis
T20	KEYPHRASE-NOTYPES 516 526	arthralgia
T21	KEYPHRASE-NOTYPES 528 548	cognitive impairment
T22	KEYPHRASE-NOTYPES 554 564	neuropathy
T23	KEYPHRASE-NOTYPES 568 589	similar investigation
T24	KEYPHRASE-NOTYPES 605 623	Westchester County
T25	KEYPHRASE-NOTYPES 625 633	New York
T26	KEYPHRASE-NOTYPES 665 673	patients
T27	KEYPHRASE-NOTYPES 686 693	percent
T28	KEYPHRASE-NOTYPES 699 715	persistent signs
T29	KEYPHRASE-NOTYPES 720 728	symptoms
T30	KEYPHRASE-NOTYPES 765 790	musculoskeletal disorders
T31	KEYPHRASE-NOTYPES 803 811	patients
T32	KEYPHRASE-NOTYPES 817 833	ongoing problems
T33	KEYPHRASE-NOTYPES 842 849	percent
T34	KEYPHRASE-NOTYPES 866 883	important fatigue
T35	KEYPHRASE-NOTYPES 888 898	arthralgia
T36	KEYPHRASE-NOTYPES 908 922	chief symptoms
T37	KEYPHRASE-NOTYPES 930 951	retrospective studies
T38	KEYPHRASE-NOTYPES 978 987	attention
T39	KEYPHRASE-NOTYPES 1006 1035	minor post-treatment symptoms
T40	KEYPHRASE-NOTYPES 1046 1056	arthralgia
T41	KEYPHRASE-NOTYPES 1061 1068	fatigue
T42	KEYPHRASE-NOTYPES 1098 1112	administration
T43	KEYPHRASE-NOTYPES 1130 1152	parenteral antibiotics
T44	KEYPHRASE-NOTYPES 1157 1175	early Lyme disease
T45	KEYPHRASE-NOTYPES 1191 1200	incidence
T46	KEYPHRASE-NOTYPES 1219 1234	Mild arthralgia
T47	KEYPHRASE-NOTYPES 1236 1243	fatigue
T48	KEYPHRASE-NOTYPES 1249 1257	headache
T49	KEYPHRASE-NOTYPES 1275 1282	therapy
T50	KEYPHRASE-NOTYPES 1288 1311	intravenous ceftriaxone
T51	KEYPHRASE-NOTYPES 1316 1331	oral penicillin
T52	KEYPHRASE-NOTYPES 1342 1352	arthralgia
T53	KEYPHRASE-NOTYPES 1369 1383	oral treatment
T54	KEYPHRASE-NOTYPES 1389 1400	amoxicillin
T55	KEYPHRASE-NOTYPES 1406 1416	probenecid
T56	KEYPHRASE-NOTYPES 1425 1436	doxycycline
T57	KEYPHRASE-NOTYPES 1446 1450	year
T58	KEYPHRASE-NOTYPES 1457 1466	treatment
T59	KEYPHRASE-NOTYPES 1472 1489	cefuroxime axetil
T60	KEYPHRASE-NOTYPES 1493 1504	doxycycline
T61	KEYPHRASE-NOTYPES 1523 1530	percent
T62	KEYPHRASE-NOTYPES 1534 1542	patients
T63	KEYPHRASE-NOTYPES 1556 1567	persistence
T64	KEYPHRASE-NOTYPES 1571 1593	mild-to-severe fatigue
T65	KEYPHRASE-NOTYPES 1595 1605	arthralgia
T66	KEYPHRASE-NOTYPES 1611 1618	myalgia
